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Abstract: Dronedarone, a new Class III antiarrhythmic agent, has now been approved by 
the US Food and Drug Administration for use in patients with atrial fibrillation or atrial 
flutter. Approval  came  in  March  2009  due  to  the  positive  results  of  the ATHENA  trial 
showing significant reductions in all-cause mortality and cardiovascular hospitalization with 
dronedarone use. A post hoc analysis of the ATHENA data also suggested a decrease in stroke 
risk with this agent. However, due to safety concerns in the heart failure population in the 
earlier ANDROMEDA trial, dronedarone is not recommended for patients with an ejection 
fraction ,35% and recent decompensated heart failure. Dronedarone is an amiodarone analog 
with multichannel blocking electrophysiologic properties similar to those of amiodarone, but 
several structural differences. Dronedarone’s lack of the iodine moiety reduces its potential for 
thyroid and pulmonary toxicity. Preliminary data from the DIONYSOS trial, and an indirect 
meta-analysis  comparing  amiodarone  with  dronedarone,  showed  amiodarone  to  be  more 
effective in maintaining sinus rhythm, while dronedarone was associated with fewer adverse 
effects resulting in early termination of the drug. Dronedarone is the first antiarrhythmic 
drug for the treatment of atrial fibrillation and atrial flutter shown to reduce cardiovascular 
hospitalizations. In patients with structural heart disease who have an ejection fraction .35% 
and no recent decompensated heart failure, dronedarone should be considered earlier than 
amiodarone in the treatment algorithm.
Keywords: dronedarone, amiodarone, atrial fibrillation, atrial flutter
Introduction
Atrial fibrillation is the most common arrhythmia requiring medical therapy, and a 
frequent cause of hospitalization. The number of people with atrial fibrillation in the 
US is projected to rise significantly in the future, reaching 16 million in 2050.1 The 
number of hospitalizations for atrial fibrillation has risen precipitously over the past 
few decades.2 Considering the morbidities associated with atrial fibrillation, including 
stroke and heart failure, the cost of health care for these patients is huge.
Initial management decisions for patients with atrial fibrillation include choosing 
rate or rhythm control, and determining stroke risk. The results of AFFIRM (Atrial 
Fibrillation Follow-up Investigation of sinus Rhythm Management) justified the 
use of rate control in older patients. The AFFIRM trial found no significant differ-
ence in mortality or stroke rate between the treatment strategies of rate or rhythm 
control.3 However, the mean age of patients in this study was 70 years, and the 
patients enrolled were fairly asymptomatic. These results may not apply to younger 





  antiarrhythmic drug therapy may be the best approach. 
However, enthusiasm for antiarrhythmic drug therapy is 
tempered by the knowledge that this route is not without 
the potential risk of   proarrhythmia or drug toxicity. A post 
hoc analysis of the AFFIRM data revealed that although 
maintenance of sinus rhythm was associated with better 
survival, this benefit was neutralized by increased mortality 
from antiarrhythmic drug use.4
The 2006 guidelines5 for the management of atrial 
fibrillation included an algorithm for the use of antiarrhythmic 
drugs in the maintenance of sinus rhythm. This algorithm 
recommended drugs appropriate in specific cardiac disease 
states. The guidelines also advised inhospital initiation 
of drugs with significant potential for causing torsades 
de pointes. The older Vaughan-Williams Class IA drugs 
(disopyramide, quinidine, and procainamide) must be 
initiated in hospital because they prolong repolarization 
and the QT interval. They are not listed in the algorithm, 
and they are becoming increasingly difficult to obtain, due 
to drug companies having discontinued their manufacture. 
The Class IC agents (flecainide and propafenone) can be 
initiated on an outpatient basis, but in the guidelines they are 
only recommended for patients with lone atrial fibrillation 
without structural heart disease. Class III antiarrhythmic 
drugs (sotalol and dofetilide) can be used in patients with 
structural heart disease and in heart failure patients. However, 
due to their QT prolongation and risk of torsades de pointes, 
inhospital initiation is required. Since they are both cleared 
renally, the dose has to be adjusted according to creatinine 
clearance. Therefore, some patients cannot safely receive 
these drugs. For patients with structural heart disease who 
have renal disease or a prolonged baseline QTc interval, 
their only antiarrhythmic drug option has been amiodarone. 
Although this is our most effective drug for the treatment of 
atrial fibrillation, significant end-organ toxicities can limit 
its use in many patients. More treatment options have been 
needed to increase the quality of life in patients with symp-
tomatic atrial fibrillation, while also decreasing morbidity 
and medical costs. Dronedarone, a new Class III agent, has 
now been approved by the Food and Drug Administration 
(FDA) for use in patients with atrial fibrillation.
Electrophysiologic properties  
and pharmacokinetics
Dronedarone is an amiodarone analog with similar 
  multichannel blocking electrophysiologic properties. Like 
amiodarone, it has predominantly Class III effects,   inhibiting 
the potassium currents IKr, IKs, IK1, and IK-Ach. The drug also 
blocks sodium and slow L-type calcium channels,6 and has 
antiadrenergic effects.7 In spite of these similarities, the 
blocking effects of the two drugs are not equivalent. In vitro 
data show dronedarone has a stronger inhibitory effect on the 
peak sodium current8 and acetylcholine-activated potassium 
current than amiodarone.9
Dronedarone differs structurally from amiodarone in that 
the iodine moiety has been removed and a methane-sulfonyl 
group has been added. These modifications were made in 
an effort to reduce the end-organ adverse effects associated 
with amiodarone. Additionally, the methane-sulfonyl group 
makes dronedarone less lipophilic, greatly shortening its 
half-life.6,10
Based on data from clinic trials, the only   recommended 
dose is 400 mg twice daily. As with amiodarone,   dronedarone’s 
absorption is increased 2 to 3 times when taken with food. 
Steady-state plasma concentration is reached in five days, 
and the half-life is approximately 24 hours. There is exten-
sive first-pass hepatic metabolism through the CYP450 
system. Dronedarone is both a substrate for and an inhibitor 
of CYP3A4. It is also a CYP2D6 inhibitor, and can inhibit 
P-glycoprotein transport. Therefore, caution should be used 
in the setting of other drugs metabolized by these hepatic 
CYP450 systems. There is an almost 2-fold increase in 
digoxin levels and a 2- to 4-fold increase in simvastatin levels 
when these agents are used with dronedarone. Beta-blockers 
and calcium channel blockers (diltiazem and verapamil) also 
interact with this antiarrhythmic drug.11 Because these are all 
cardiovascular drugs frequently used in patients being treated 
for atrial fibrillation, physicians need to be aware of these 
interactions and adjust the doses to help prevent bradycardia 
or potential toxicity. Table 1 lists the main cardiovascular 
drugs, along with the enzyme pathway involved in their 
metabolism. Table 1 also outlines the resulting interaction, 
and the suggested dose adjustment when they are used with 
Table 1 Cardiovascular drug interactions with dronedarone
Drug Enzyme pathway Effect Dose adjustment
Digoxin P-glycoprotein (substrate) 2.5-fold increase in digoxin level Halve the digoxin dose
Verapamil, diltiazem CYP3A (inhibitors) 1.4- to 1.7-fold increase in dronedarone level Lower dose of calcium channel blocker
Beta-blockers CYP2D6 (substrate) 1.6-fold increase in metoprolol level Lower beta-blocker dose
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dronedarone. Overall, drug interactions associated with 
dronedarone are minimal when compared with amiodarone. 
There is no significant warfarin interaction. Like amiodarone, 
dronedarone partially inhibits the tubular organic cation 
transport of creatinine, resulting in increased serum creatinine 
levels, despite unchanged glomerular filtration rate.12
Clinical trials
The initial dronedarone trials were DAFNE (Dronedarone 
Atrial FibrillatioN Study after Electrical cardioversion), 
EURIDIS (EURopean trial In atrial fibrillation or flutter 
patients receiving Dronedarone for the maIntenance of Sinus 
rhythm), ADONIS (American-Australian-African trial with 
DronedarONe In atrial fibrillation/flutter patients for the 
maintenance of Sinus rhythm), and ERATO (Efficacy and 
safety of dRonedArone for The cOntrol of ventricular rate 
during atrial fibrillation). These trials were designed to help 
establish the efficacy, dosage, and rate control with drone-
darone. In DAFNE, doses of 400 mg, 600 mg, or 800 mg were 
given twice daily. The lowest dose was found to have the best 
efficacy, and was better tolerated with fewer gastrointestinal 
side effects.13 Based on these results, the dosage of 400 mg 
twice daily was used in EURIDIS and ADONIS.14 These 
trials demonstrated both a significant increase in the median 
time to first recurrence of atrial fibrillation, and a decrease in 
ventricular response during atrial fibrillation recurrences. The 
ERATO trial further established dronedarone’s effectiveness 
in rate control of permanent atrial fibrillation.15
ANDROMEDA (Antiarrhythmic trial with DROnedarone 
in Moderate to severe congestive heart failure Evaluating 
morbidity DecreAse) was a mortality study which was termi-
nated early due to the dronedarone-treated group having twice 
the mortality rate of the placebo group. In the dronedarone-
treated group, only 37% had a history of atrial fibrillation, 
but 62% had New York Heart   Association Class III or IV 
congestive heart failure. The study population comprised 
patients hospitalized for decompensated heart failure, and 
the dosage used was 400 mg twice a day.16 It has been pos-
tulated that the rise in creatinine in the dronedarone-treated 
group led to discontinuation of their angiotensin-converting 
enzyme inhibitors and other of their heart failure medicines. 
Although this could possibly explain the increase in mortality, 
an equally plausible explanation is that dronedarone worsened 
heart failure through a negative inotropic effect in this high 
risk-population.17
A large safety trial was designed to test whether 
  dronedarone could be used in patients with atrial fibrillation and 
structural heart disease, ie, ATHENA (A   placebo-  controlled, 
double-blind, parallel arm Trial to assess the efficacy of drone-
darone 400 mg twice daily for the prevention of cardiovascu-
lar Hospitalization or death from any cause in patiENts with 
Atrial fibrillation/atrial flutter). The study enrolled patients 
with persistent or paroxysmal atrial fibrillation, and at least 
one cardiovascular risk factor. The same dose (400 mg twice 
daily) was used in this study as in ANDROMEDA. Patients 
with Class IV or recently decompensated heart failure were 
excluded. In contrast with the subjects in ANDROMEDA, 
only 4.4% of those in ATHENA had Class III heart failure. 
The results of ATHENA were significant reductions in the 
primary endpoints of all-cause mortality and cardiovascular 
hospitalization. The hazard ratio for the primary outcome 
in the dronedarone group was 0.76. The reduced rate of 
hospitalizations due to cardiovascular events was mainly 
attributed to fewer admissions for atrial fibrillation. In the 
dronedarone-treated group, the only significant adverse side 
effects were nausea, diarrhea, bradycardia, rash, increase in 
serum creatinine, and QT prolongation (Table 2). The rates 
of thyroid and pulmonary adverse events were no different 
from placebo.18 Based on these positive results, dronedarone 
was approved by the FDA in March 2009. However, its use 
is limited to a lower-risk group with an EF . 35% without 
decompensated heart failure. Since the ATHENA population 
was significantly healthier than the ANDROMEDA group, 
the ATHENA safety data cannot be automatically applied to 
patients with unstable heart failure.17
A post hoc analysis of the ATHENA data was done to 
investigate the effect of dronedarone on stroke risk in this 
population. The mean CHADS2 score was 2 in both the 
dronedarone and placebo groups. At baseline, 60% of the 
patients were being treated with oral anticoagulant therapy. 
The risk of stroke per year was 1.2% in the dronedarone 
group,   compared with 1.8% in the control group, with a 
hazard ratio of 0.66 and P = 0.027. The reduced risk of 
stroke was similar, regardless of oral anticoagulant use. 
The relative risk of stroke was significantly decreased in 
Table 2 Side effects of dronedarone*







Serum creatinine increase 51%
Notes:  *These data are based on a 400 mg twice daily dose of dronedarone in 
ATHeNA, eURiDeS, ADONiS, eRATO, and DAFNe studies.13–15,18 





patients with a CHADS2 score of $2, compared with those 
with lower CHADS2 scores.19 A limitation of this analysis 
is that stroke was not a prespecified primary outcome of 
ATHENA. Therefore, the observation of decreased stroke 
risk in this post hoc analysis should be viewed with caution. 
Further studies designed to investigate this hypothesis are 
warranted.
In previous studies, no antiarrhythmic drugs have been 
found to reduce the risk of stroke in atrial fibrillation patients. 
Antiarrhythmic drugs were found to decrease the recurrence 
of atrial fibrillation in the AFFIRM trial. The lack of benefit 
in reducing stroke risk was thought to be most likely due to 
underuse of warfarin in the group treated with antiarrhythmic 
drugs.20 The decreased stroke risk in the dronedarone-treated 
group in the ATHENA trial could be attributed to reduction of 
atrial fibrillation frequency. Dronedarone’s modest reduction 
of blood pressure, and more substantial decrease in heart rate 
during atrial fibrillation are other potential mechanisms of 
decreased stroke risk.19
Efficacy of dronedarone
Due to dronedarone’s chemical and electrical similarities to 
amiodarone, it is natural to want to compare efficacy between 
the two drugs. Freedom from recurrent atrial fibrillation was 
not an endpoint in the ATHENA trial, thereby limiting infor-
mation on efficacy compared with placebo in that population. 
Critics were disappointed that the ATHENA trial was not 
designed as a head-to-head comparison of dronedarone and 
amiodarone. However, the DIONYSOS (Efficacy and Safety 
of Dronedarone Versus Amiodarone for the Maintenance of 
Sinus Rhythm in Patients With Atrial Fibrillation) trial was 
conducted,17 partly to fulfill the requirements of the   European 
Medicines Agency. This trial, comparing the efficacy of 
dronedarone versus amiodarone in the treatment of atrial 
fibrillation, has recently concluded. After a mean follow-up 
period of seven months, amiodarone was found to be more 
effective in maintaining sinus rhythm than was dronedarone. 
Atrial fibrillation recurrence with dronedarone was 63.5% 
compared with 42.0% in the amiodarone-treated group. On 
the other hand, dronedarone use was associated with fewer 
adverse effects and less premature termination of the drug. 
While intolerance to dronedarone was mainly secondary to 
gastrointestinal side effects, thyroid and neurologic events 
(tremor and sleep disorder) were mostly responsible for 
discontinuation of amiodarone.21
An indirect meta-analysis has also been published22 
using 4 placebo-controlled trials of amiodarone and 4 
  placebo-controlled trials of dronedarone. Also included in this 
analysis were direct randomized data from the DIONYSOS 
trial.21 The authors used indirect comparison meta-analysis 
and normal logistic meta-regression models to compare the 
efficacy and safety of dronedarone with amiodarone.22 The 
results were similar to the data from the DIONYSOS trial 
alone. Dronedarone was less effective than amiodarone for 
the maintenance of sinus rhythm, but was associated with 
fewer adverse side effects necessitating discontinuation of the 
drug. Additionally, there was a trend toward greater all-cause 
mortality associated with amiodarone use. In dronedarone-
treated patients, the incidence of end-organ toxicity, or symp-
tomatic bradycardia resulting in termination of the drug, was 
not statistically different compared with the placebo group. 
However, the incidence of pulmonary and liver toxicity in the 
amiodarone users requiring drug   discontinuation was also no 
different from placebo.22 Because in this analysis the average 
follow-up of the trials was one year and in the DIONYSOS 
trial the duration of follow-up was only 6 months, we do not 
know what the long-term difference in adverse events will 
be. To weigh the risks and benefits of these two drugs more 
accurately, more long-term follow-up data are needed.
Safety and surveillance
Although dronedarone prolongs the QT interval, the risk of 
torsades de pointes is low. There were no cases of torsades 
de pointes reported in the DIONYSOS trial,23 and only one 
case in the ATHENA trial.18 Similar to amiodarone, the low 
risk of torsades de pointes allows outpatient initiation of the 
drug. However, the risk of proarrhythmia could significantly 
increase in the setting of a QTc interval .500 msec. Patients 
with a prolonged QTc were excluded from the drug trials. 
Dronedarone should not be used in conjunction with other 
drugs that prolong the QT interval, and should be used cau-
tiously with drugs known to interact with dronedarone. Peri-
odic electrocardiograms to monitor patients for a prolonged 
QT interval and bradycardia are recommended. Patients should 
be instructed to take dronedarone with food to increase absorp-
tion, and to avoid grapefruit juice, which can increase serum 
levels of this drug. Unlike amiodarone users, dronedarone 
patients do not need to be monitored for possible thyroid, liver, 
or pulmonary toxicity. Obviously, patients with severe baseline 
hepatic impairment should not take dronedarone, because the 
drug is metabolized by the CYP450 system. As with all antiar-
rhythmic drugs, dronedarone has not been studied in pregnant 
women. However, the drug has been found to be teratogenic 
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for use during pregnancy. Due to the increased mortality in 
dronedarone-treated patients in the   ANDROMEDA trial, 
there is a black box warning in the package insert against the 
use of the drug in patients with New York Heart Association 
Class IV heart failure, or Class II–III heart failure with a recent 
  decompensation requiring hospitalization or referral to a heart 
failure specialist. Table 3 summarizes the contraindications to 
dronedarone use. These data are based on exclusion criteria 
from the dronedarone clinical trials.16,18
Clinical role of dronedarone
Ten years after the approval of dofetilide, the FDA approved 
dronedarone in 2009 to reduce the risk of cardiovascular 
hospitalization in patients with paroxysmal or persistent 
atrial fibrillation or atrial flutter. Some advantages of this new 
antiarrhythmic drug include outpatient initiation, as well as 
less need for surveillance for end-organ toxicity and fewer 
drug interactions. There is a single recommended dose which 
can be started on an outpatient basis due to the low risk of 
proarrhythmia. While electrocardiograms should be periodi-
cally obtained, no chest X-rays or laboratory tests to monitor 
thyroid and hepatic function are required. Since there is no 
significant interaction with warfarin, more frequent monitor-
ing of coagulation is not needed. Dronedarone is generally 
well tolerated. Gastrointestinal side effects are the most com-
mon, but were responsible for discontinuation of the drug in 
only 3.2% of patients in clinical trials.24 These factors, along 
with fewer hospitalizations and decreased stroke risk seen 
in the ATHENA trial,18,19 may result in a decreased cost of 
treatment in dronedarone patients. However, no cost-efficacy 
analyses have been done to confirm this theory. On the less 
positive side, DIONYSOS and other meta-analyses have 
shown dronedarone to be less effective than amiodarone in 
preventing recurrence of atrial fibrillation.22,23 Important to 
remember were the safety concerns for decompensated heart 
failure patients in the ANDROMEDA trial.16
Although less efficacious than amiodarone in the 
  prevention of recurrent atrial fibrillation, dronedarone 
reduces the risk of cardiovascular hospitalization. It is a safer, 
well tolerated drug in patients without   decompensated heart 
  failure. Dronedarone can be considered as an   alternative 
  therapy to amiodarone, and tried prior to amiodarone, 
  especially in younger patients. It is also an obvious choice 
for patients who have developed toxicities from amiodarone. 
Table 4 summarizes the similarities and differences between 
dronedarone and amiodarone. Prior to the approval of 
dronedarone, the only antiarrhythmic drug alternatives for 
patients with structural heart disease who were intolerant to 
amiodarone were either sotalol or dofetilide. These drugs 
require inpatient initiation, and cannot be used in patients 
with significant renal failure. Due to the risk of torsades de 
pointes associated with these drugs, and the long half-life 
of amiodarone, physicians have typically waited a month or 
more to start dofetilide or sotalol after stopping amiodarone. 
In the ATHENA trial,18 patients had to stop amiodarone at 
least a month prior to enrollment in the trial. The earlier 
EURIDIS and ADONIS trials14 allowed patients to be 
enrolled immediately after discontinuation of amiodarone. 
Physicians are currently using their clinical judgment in 
deciding the optimal amiodarone washout period for each 
Table 3 indications and contraindications for dronedarone use*
Indications
To reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation or atrial flutter
Contraindications
• NYHA Class iV heart failure, or Class ii–iii with recent decompensation requiring hospitalization or referral to heart failure specialist
• Second or third degree AV block or SND without a pacemaker
•   Concomitant use of strong CYP 3A inhibitors (such as ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, 
nefazodone, and ritonavir)
• Concomitant use of QT-prolonging drugs or herbal products
• Baseline prolonged corrected QT interval (.500 msec) or PR interval (.280 msec)
• Severe hepatic dysfunction
• Women who are pregnant or may become pregnant (Category X)
Relative contraindications
• New or worsening heart failure during treatment
• Hypokalemia or hypomagnesemia
• Corrected QT interval $500 msec on dronedarone
Notes: *Data are based on exclusion criteria for dronedarone clinical trials.16,18 Adapted from the prescribing information approved by the US Food and Drug Administration.





patient. The ARTEMIS trial has been designed to answer this 
question. Enrolled patients will switch from amiodarone to 
dronedarone either immediately, or with one week or one 
month delay. No one is advocating this switch in patients 
whose atrial fibrillation is controlled and they are not expe-
riencing any adverse effects on amiodarone.
Conclusion
Dronedarone can be considered as a first-line therapy for 
atrial fibrillation or atrial flutter in patients with structural 
heart disease, who have an EF . 35% and no recent decom-
pensated heart failure. Although it is less efficacious than 
amiodarone in maintaining sinus rhythm, dronedarone is the 
first drug therapy for atrial fibrillation or atrial flutter shown 
to reduce the rate of cardiovascular hospitalizations. This is 
likely due to fewer arrhythmia episodes and better tolerated 
atrial fibrillation recurrences. Theoretically, dronedarone use 
should result in lower health care cost for atrial fibrillation 
patients due to its favorable safety profile, lowering of 
stroke risk, and reduction in cardiovascular hospitalizations. 
Dronedarone provides an additional pharmacological option 
in patients with atrial fibrillation, which can be considered 
earlier than amiodarone in the treatment algorithm.
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